Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics crawled time : 13:47 save search
XORTX Presents New Proof of Concept Data at American Society of Nephrology
Published: 2022-11-03 (Crawled : 13:47) - xortx.com
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
|
| O: 4.88%
H: 4.65%
C: -6.87%
XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study
Published: 2022-11-28 (Crawled : 13:47) - xortx.com
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.73%
H: 6.19%
C: -3.08%
study
XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-12-08 (Crawled : 13:47) - xortx.com
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.0%
H: 0.0%
C: -2.86%
disease kidney
XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression
Published: 2023-01-03 (Crawled : 13:47) - xortx.com
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
|
| O: 14.52%
H: 0.0%
C: -11.37%
risk patent disease kidney
FDA approves selinexor for refractory or relapsed multiple myeloma
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
KPTI | $1.38 25.46% 20.0% 3M
|
Health Technology
|
| O: 1.61%
H: 0.09%
C: -3.73%
fda approval fda approval
FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
YMAB | $15.11 -0.2% -0.33% 400K
|
Health Technology
|
| O: 0.05%
H: 1.54%
C: -3.36%
risk fda granted approval grant
Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates
Published: 2020-05-11 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: -11.92%
H: 1.09%
C: -3.58%
results
National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent
Published: 2020-05-18 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 5.15%
H: 5.17%
C: 5.09%
respiratory blood
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Published: 2020-05-27 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 1.42%
H: 2.3%
C: -1.01%
conference presentation therapeutics
Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)
Published: 2020-05-29 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 2.95%
H: 36.92%
C: 30.08%
positive acquired treatment chmp lefamulin
Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Published: 2020-05-29 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
| Email alert
Add to watchlist
offering nasdaq
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection
Published: 2020-06-20 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
| Email alert
Add to watchlist
injection fda response
Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.
Published: 2020-07-15 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 53.38%
H: 12.75%
C: -17.65%
distribution
XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia
Published: 2020-07-16 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 15.61%
H: 1.74%
C: -6.11%
acquired approval treatment lefamulin health
Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study
Published: 2020-07-23 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 4.68%
H: 0.25%
C: -1.45%
lefamulin preclinical pre-clinical
NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)
Published: 2020-07-28 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: -1.23%
H: 11.87%
C: 2.5%
acquired approval treatment lefamulin
Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Published: 2020-07-30 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: -0.51%
H: 1.71%
C: -0.63%
Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020
Published: 2020-08-03 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 1.32%
H: 1.16%
C: 0.78%
results
Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
Published: 2020-08-06 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: -4.94%
H: 0.0%
C: -4.56%
results
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
Published: 2020-08-31 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: -1.68%
conference therapeutics
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.